Company intelligence / Profile preview

Blue Earth Therapeutics

Oxford, United Kingdomblueearththerapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company recently completed a Phase 1 clinical trial for its lead candidates and has initiated a Phase 2 clinical trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 injection in metastatic castrate-resistant prostate cancer. First results from the Phase 2 study could be available as soon as H1 2026[6].

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalsRadioligand Therapies
Industry: Biotech

Drug pipeline

8 assets

lutetium (177Lu) rhPSMA-10.1

7 more assets in the full pipeline.

Request access →

Partnerships

University College London (UCL)

Beyond the preview

Go deeper on Blue Earth Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Earth Therapeutics.

Explore the full profile